GlassScriptPhysician profile
Marc A Seltman
NPI 1821164872
$1,843.78
in general payments reported to CMS, 2019-2025
26 companies · $149 in 2025
The $149 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $419 · 2020: $236 · 2021: $434 · 2022: $123 · 2023: $173 · 2024: $310 · 2025: $149.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $632.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $631.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $334.53 | 2019-2021 | |
| Pfizer INC. | $187.76 | 2019-2024 | |
| Astellas Pharma US INC | $139.31 | 2021-2024 | Veozah |
| Merck Sharp & Dohme LLC | $112.20 | 2019-2025 | M-M-R II, Capvaxive, Gardasil 9 |
| Novo Nordisk INC | $103.29 | 2019-2024 | Wegovy, Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $93.56 | 2019-2023 | Jardiance, Synjardy, Tradjenta |
| Glaxosmithkline, LLC. | $88.74 | 2020-2024 | Trelegy Ellipta |
| Biohaven Pharmaceuticals, INC. | $83.10 | 2021 | |
| Esperion Therapeutics, INC. | $74.93 | 2021-2025 | Nexletol |
| Exact Sciences Corporation | $66.71 | 2024-2025 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals LP | $63.74 | 2019-2024 | Breztri, Airsupra |
| Amarin Pharma, INC. | $61.07 | 2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $57.77 | 2022 | |
| Novartis Pharmaceuticals Corporation | $48.36 | 2024-2025 | |
| Lilly USA, LLC | $39.14 | 2022-2025 | Kisunla |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $35.91 | 2024 | Xifaxan, Trulance |
| Kowa Pharmaceuticals America, INC. | $33.85 | 2019-2020 | |
| Medicure Pharma INC. | $29.82 | 2021 | |
| Eisai INC. | $28.14 | 2021 | |
| Horizon Therapeutics Plc | $28.02 | 2023 | Krystexxa |
| Amneal Pharmaceuticals LLC | $28.02 | 2021 | |
| Dexcom, INC. | $23.56 | 2024 | Dexcom G6 Transmitter |
| Sumitomo Pharma America, INC. | $22.66 | 2025 | Gemtesa |
| Allergan, INC. | $21.59 | 2019 | |
| Baxter Healthcare | $20.50 | 2024 | Hillrom - Connex Spot Monitor |
| Antares Pharma, INC. | $17.50 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marc Seltman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.